In a unified effort to strengthen Europe’s position in global trade, nearly three dozen pharmaceutical companies have called on the European Commission to support the sector as it navigates potential U.S. tariff measures. The move highlights the industry’s proactive approach to preserving strong transatlantic trade ties and ensuring continued growth within the EU.
The companies addressed a letter to Commission President Ursula von der Leyen, outlining recommendations to reinforce Europe’s competitiveness in the face of evolving global trade dynamics. Key proposals include simplifying regulatory processes, supporting innovation, and reviewing upcoming environmental fees that may affect production costs.
Despite anticipated trade shifts, the pharmaceutical industry remains optimistic. With €90 billion in medical and pharmaceutical exports to the United States in 2023, the EU continues to play a leading role in global healthcare trade. The industry leaders emphasized the need to maintain this momentum by creating a more efficient and innovation-friendly environment within Europe.
The letter also reaffirms the sector’s commitment to staying rooted in the EU while continuing to serve global markets. By working in partnership with the European Commission, these companies aim to ensure that Europe remains a competitive, forward-thinking hub for pharmaceutical development and export.
This initiative showcases the industry’s readiness to collaborate with policymakers to protect long-term trade stability and support economic growth throughout the region.
#ITCNewsUpdates #BreakingNews #TradeNews #NewsUpdate #PharmaTrade #PositiveNews #TariffUpdate